In one randomized clinical trial, cholinergic augmentation with a reversible and noncompetitive cholinesterase inhibitor (donepezil, at 10 mg/day for six weeks) did not affect measures of static or dynamic balance in people with PD [193]. This evidence concerns the gene BCHE and Parkinson disease.